July 22, 2024

NRG Oncology Broadcast archives are accessible from our website at any time. Please bookmark this link for your convenience.

NRG 2024 Summer Meeting Registration is Open!

Join us for the NRG Oncology Summer Meeting July 25th - July 27th at the Sheraton Denver Downtown Hotel in Denver, CO. The Meeting will be held in-person only (with limited virtual session offerings). REGISTER TODAY!

Virtual Sessions Start Today!

Are you attending any of the NRG2024 virtual sessions? Our zoom links to join our virtual sessions are now available! Read more here

Summer 2024 Symposium “Novel, Next and Now: Checkpoint Inhibitors and

Cellular Immunotherapy Progress in Oncology”

Join us in-person or virtually! Thursday, July 25, 2024, 8am to 12pm MDT.

Speakers will focus their presentations on the current state of immunotherapy focusing on gynecologic malignancies, future immunotherapy options beyond checkpoint inhibitors with lessons learned from non-gynecologic malignancies, and how to establish successful phase I and cellular therapy teams in both academic and community settings.

NRG-BR008/HERO Workshop

Please join the NRG-BR008 study PIs, Dr. Lior Braunstein and Dr. Melissa Mitchell for the NRG-BR008/HERO Study Workshop being held at the NRG2024 meeting in Denver on Saturday, July 27, at 8-9am MDT in PLAZA / Plaza CF. For more information about this workshop and other BR008 sessions, please view the flyer posted here. 

NRG Oncology Protocol Support Committee (PSC) – Educational Sessions

Please be sure to sign up to attend the PSC Sessions being held during the NRG Oncology Summer Meeting in Denver. The PSC will host a Continuing Education session and Roundtable presentations on Thursday, July 25; and a Protocol Spotlight Session (NRG-CC011, NRG-GI008, NRG-BR008) on Friday, July 26. Please refer to the posted session flyers and agendas (login required) for more details about the PSC programing offered at #NRG2024. The PSC programming at #NRG2024 has been approved by the Virginia Nurses Association to award contact hours. The Virginia Nurses Association is accredited as an approver of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Cancer Prevention and Control Committee - Guest Speaker

The NRG Oncology Cancer Prevention and Control (CPC) committee is pleased to announce a guest speaker during the upcoming meeting. Join us in-person on Thursday, July 25, 1 – 2:30pm. Dr. Carmen Guerra, Vice Chair of Diversity and Inclusion, Department of Medicine, University of Pennsylvania will be speaking on “Overcoming Barriers to Diverse Representation in Cancer Clinical Trials.”

AMENDMENTS

CANER PREVENTION & CONTROL

NRG-CC009: Amendment 2: August 9, 2023; Amendment 3: June 5, 2024 (posted on CTSU)

GYNECOLOGIC

NRG-GY019: Amendment 4; version date: June 6, 2024 (posted on CTSU)

OTHER PROTOCOL NOTICES

1. ALL DISEASE SITES

NRG-GY022: Reminder: Actively Recruiting MALE Patients only Read More

2. BIOSPECIMEN BANKS

Printing Biospecimen Transmittal PDFs from Rave

Please note an effort is underway to clarify how to obtain a Biospecimen Transmittal PDF for submission to the NRG Oncology Biospecimen Bank. Read More

Shipping samples in extreme weather conditions

The NRG Oncology Biospecimen Bank staff would like to remind you to keep in mind weather conditions when shipping samples. 

• Be sure to add sufficient dry ice to frozen shipments. In extreme temperatures, if possible, store the samples in -80° C until the temperature comes down.
• Frozen biospecimens should be shipped to the bank on Monday through Wednesday for Tuesday through Thursday delivery.
• Do not ship any biospecimens the day before a holiday. Watch the NRG Weekly Broadcasts for holiday closure notices and instructions.
• Be aware of the weather conditions in your area and where the biospecimens will be shipped.
• In temperatures over 80° F, use a cool pack when shipping FFPE blocks.
• Always refer to the protocol or manual (Biospecimen Collection and Submission Manual or Pathology and Correlatives Manual) for shipping instruction.  

3. BREAST

NRG-BR004: Memorandum, dated July 22, 2024, regarding Important Data Management Information (posted on CTSU)

NRG-BR008/HERO: The NRG-BR008 Study Team would like to understand more about the obstacles sites are facing in enrolling patients to the study. In addition, if your site has not opened the study, we want to learn the reasons for your choice. Please click here to take this short, 1-minute survey so we can better appreciate your challenges and consider potential solutions.

4. CANCER PREVENTION & CONTROL

NRG-CC010: The study is open to NRG sites in Japan and South Korea. The optional biospecimen collection does not apply to sites participating in these countries.

5. GENITOURINARY

NRG-GU008: Spanish Translated Informed Consent Form and CIRB approval of Translation (posted on CTSU)

6. GYNECOLOGIC

NRG-GY007: CLARIFICATION - Study has not been terminated. Sites should continue to conduct patient follow-up as outlined in the protocol.

NRG-GY018: There are unstained slides remaining at NeoGenomics for some patients. If your site would like these unstained slides returned, please email Colleen Austin (colleen.austin@merck.com) by COB on July 23, 2024, with the following information: Patient ID and Accession Number.

NRG-GY026: Please note, the post-chemo cfDNA Whole Blood (WB03) should only be collected if the Pre-Treatment cfDNA Whole Blood (WB01) was collected.

NRG-GY028: ETCTN has approved the submission of unstained slides when a block absolutely cannot be submitted. This will be included in the next protocol amendment. Until such time, details regarding this alternate submission can be found here.

NRG-GY031: Please note, there is an error in the section 4.2 table and the Biospecimen Collection and Submission Manual. The Part I PK collection is to be done on Cycle 1, Day 1, and Cycle 1, Day 8. This will be updated with the next amendment.

7. HEAD & NECK

NRG-HN008: Reminder! Please update treatment and AE data weekly. This is a Phase I trial and timely data submission is very important.

8. LUNG

NRG-LU008: Sites in Canada – Amendment 1 has been approved by Health Canada. The NOL is posted on CTSU. Please complete and submit the updated Protocol Signature Page and CTSI via the CTSU regulatory submission portal.

9. VTOC TRAINING

The VTOC Webinar Training Series schedule and registration is available for NRG Oncology Research Associates working on NRG-HN001, NRG-HN002, NRG-CC003, NRG-CC005, NRG-BR009, NRG-CC011, and NRG/SWOG S1914. Space is limited so register now and reserve your seat. The next webinar training is scheduled for Wednesday, August 7, 2024. The VisionTree staff will also be at the NRG 2024 summer meeting. Please look for them at the Round Table session on Thursday, July 25 1:30-4:45pm MT.

Drug Safety and Investigator's Brochure updates have been issued for the following studies:

*The current version of the Investigator Brochure Documents for Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI)-sponsored trials are available for access via the Cancer Therapy Evaluation Program (CTEP) Agent Inventory Management System (AURORA) application. Log-in using your Identity and Access Management (IAM) or ID.me credentials and provide the requested information to access the document.

Every site principal investigator is responsible for reviewing this document. The Investigator Brochure is for use by the site principal investigator and any study personnel under his/her supervision who need to know the contents for the conduct of a clinical trial, including Institutional Review Board(s) or Independent Ethics Committee(s).

NRG Member Demographics Data Collection Initiative

We are excited to introduce the NRG Member Demographics Data Collection Initiative that will allow us to create a comprehensive member database, enabling us to better understand and serve our members. Your information will be kept secure and confidential, ensuring that your privacy is always protected. All members are encouraged to complete the form or indicate that they wish to opt out of this data collection initiative. 

Scan the QR code below or click this link to access the form. 

Questions? Read more here

NEW Patient Advocate Training Available on CTSU/CLASS

NRG Oncology recently launched new patient advocate training modules on the CTSU/CLASS platform. These modules are geared towards patient advocates and include valuable information regarding NRG Oncology’s organizational structure, proceedings, and the in-and-outs of the clinical trial development process. You can find these modules by logging into CTSU and clicking the CLASS tab. For more detailed instructions, click here. 

Statistical Reports – July 2024

The July 2024 Statistical Reports for active studies are now available on the NRG Oncology website. Please note that you will need to log in with your CTEP credentials to access the study reports.  

REMINDER: Any manuscript or abstract resulting from research done under the auspices of our NCI grant awards must be processed through the NRG Publications Office before being submitted to the journal or association.

Please reach out to NRG-Publications@NRGOncology.org as a first step to ensure all requirements are met.

Please note the following upcoming meetings and abstract submission deadlines

UPCOMING MEETINGS

American Society for Radiation Oncology (ASTRO); Sep 29-Oct 2, 2024; Washington, DC

Canadian Association of Radiation Oncology (CARO); Sep 11-14, 2024; Vancouver, BC

European Society for Medical Oncology (ESMO); Sep 13-17, 2024; Barcelona, Spain

International Gynecologic Cancer Society (IGCS); Oct 16-18, 2024; Dublin, Ireland

International Society for Quality-of-Life Research (ISOQOL); Oct 13-16, 2024; Cologne, Germany

PA Breast Cancer Coalition (PBCC); Oct 15, 2024; Harrisburg, PA

Radiological Society of North America (RSNA); Dec 1-5, 2024; Chicago, IL

UPCOMING ABSTRACT SUBMISSION DEADLINES

American Association for Thoracic Surgery (AATS); May 2-5, 2025; Seattle, WA; due to publications committee Oct 7, 2024; submission deadline Oct 14, 2024, 11:59 pm ET

American Society of Clinical Oncology (ASCO); May 30-Jun 3, 2025; Chicago, IL; due to publications committee Jan 14, 2025; submission deadline Jan 28, 2025; LBA Mar 5, 2025 (placeholder required)

American Society of Clinical Oncology (ASCO) GI; Jan 23-25, 2025; San Francisco, CA; due to publications committee Sep 10, 2024; submission deadline Sep 24, 2024; LBA Oct 24, 2024 (placeholder required)

American Society of Clinical Oncology (ASCO) GU; Feb 13-15, 2025; San Francisco, CA; due to publications committee Oct 11, 2024; submission deadline Oct 15, 2024; LBA Nov 14, 2024 (placeholder required)

EORTC-NCI-AACR Symposium on Molecular Targets and therapies; Oct 23-25, 2024; Barcelona, Spain; LBA Sep 26, 2024

European Society of Gynaecological Oncology (ESGO); Feb 20-23, 2025; Rome, Italy; due to publications committee Oct 14, 2024; submission deadline Oct 28, 2024; LBA Jan 15, 2025 (placeholder required)

San Antonio Breast Cancer Society (SABCS); Dec 10-14, 2024; San Antonio, TX; LBA Sep 30, 2024, 11:59 pm CT

Society for Immunotherapy of Cancer (SITC); Nov 6-10, 2024; Houston, TX; LBA Sep 12, 2024

Society for Neuro-Oncology (SNO); Nov 21-24, 2024; Houston, TX; LBA Sep 3, 2024, 5:00 pm ET (placeholder required)

Society of Surgical Oncology (SSO) Annual Meeting; Feb 14-17, 2025; Scottsdale, AZ; due to publications committee Sep 16, 2024; submission deadline Sep 30, 2024

SSO – Advanced Cancer Therapies; Mar 27-29, 2025; Tampa, FL; due to publications committee Sep 2, 2024; submission deadline Sep 16, 2024